Neurologists seeing patients with seizures who are from developing countries in Latin America, sub-Saharan Africa and other countries with much poverty and poor sanitation should be on the lookout for neurocysticercosis, a condition related to exposure to tapeworms.
The ECTRIMS conference may be based in Europe but as the conference has grown so has its global impact on multiple sclerosis treatment. With topics ranging from newly approved therapies to those in the pipeline to those not yet ready for testing there is lots to learn in the yearly event.
Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient’s quality of life (QoL). But by how much?
Results from clinical trials that included patients with relapsing-remitting multiple sclerosis (RRMS) do not appear to be consistent for patients with primary progressive multiple sclerosis (PPMS), according to Markus W. Koch, MD, from the University of Calgary in Alberta, Canada.
It’s not uncommon for patients with multiple sclerosis (MS) to experience a reduction in brain volume. However, treatment with alemtuzumab can slow the process, according to a multi-continental team of investigators.